Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gordana Vlahovic
Efficacy of Bevacizumab Plus Erlotinib Versus Erlotinib Alone in Advanced Non-Small-Cell Lung Cancer After Failure of Standard First-Line Chemotherapy (BeTa): A Double-Blind, Placebo-Controlled, Phase 3 Trial
The Lancet
Medicine
Phase 1 Study of Ixazomib, an Investigational Proteasome Inhibitor, in Advanced Non-Hematologic Malignancies
Investigational New Drugs
Oncology
Pharmacology
Related publications
Egfr Test-Guided Erlotinib Versus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Budget Impact Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy
BMJ Open
Medicine
Phase II Study of Gemcitabine Plus Oxaliplatin as First-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer
British Journal of Cancer
Cancer Research
Oncology
P3.01-94 Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel as First-Line Therapy for Patients With Advanced Non-Small-Cell Lung Cancers
Archives of Medical Science
Medicine
A Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients With Advanced EGFR Wild-Type Non-Small Cell Lung Cancer
BMC Research Notes
Biochemistry
Medicine
Genetics
Molecular Biology
PCN37 Cost Comparison of Erlotinib Versus Generic Docetaxel in Second-Line Non-Small Cell Lung Cancer in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib
ESMO Open
Cancer Research
Oncology
Gemcitabine Plus Vinorelbine as First-Line Chemotherapy in Advanced Nonsmall Cell Lung Carcinoma a Phase II Trial
Cancer
Cancer Research
Oncology
